BRPI0919404A2 - combinações sinergísticas de um inibidor macrocíclico do hcv e de um nucleosídeo - Google Patents

combinações sinergísticas de um inibidor macrocíclico do hcv e de um nucleosídeo

Info

Publication number
BRPI0919404A2
BRPI0919404A2 BRPI0919404A BRPI0919404A BRPI0919404A2 BR PI0919404 A2 BRPI0919404 A2 BR PI0919404A2 BR PI0919404 A BRPI0919404 A BR PI0919404A BR PI0919404 A BRPI0919404 A BR PI0919404A BR PI0919404 A2 BRPI0919404 A2 BR PI0919404A2
Authority
BR
Brazil
Prior art keywords
nucleoside
synergistic combinations
hcv inhibitor
macrocyclic hcv
macrocyclic
Prior art date
Application number
BRPI0919404A
Other languages
English (en)
Inventor
Oliver Lenz
Tse-I Lin
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Publication of BRPI0919404A2 publication Critical patent/BRPI0919404A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
BRPI0919404A 2008-09-18 2009-09-18 combinações sinergísticas de um inibidor macrocíclico do hcv e de um nucleosídeo BRPI0919404A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164612 2008-09-18
PCT/EP2009/062096 WO2010031829A1 (en) 2008-09-18 2009-09-18 Synergistic combinations of a macrocyclic inhibitor of hcv and a nucleoside

Publications (1)

Publication Number Publication Date
BRPI0919404A2 true BRPI0919404A2 (pt) 2015-12-15

Family

ID=40076811

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919404A BRPI0919404A2 (pt) 2008-09-18 2009-09-18 combinações sinergísticas de um inibidor macrocíclico do hcv e de um nucleosídeo

Country Status (20)

Country Link
US (1) US20110171174A1 (pt)
EP (1) EP2341907A1 (pt)
JP (1) JP2012502956A (pt)
KR (1) KR20110054056A (pt)
CN (1) CN102164602A (pt)
AP (1) AP2011005608A0 (pt)
AR (1) AR073603A1 (pt)
AU (1) AU2009294622A1 (pt)
BR (1) BRPI0919404A2 (pt)
CA (1) CA2737835A1 (pt)
CO (1) CO6351740A2 (pt)
EA (1) EA201170456A1 (pt)
EC (1) ECSP11010902A (pt)
IL (1) IL211599A0 (pt)
MX (1) MX2011002896A (pt)
PA (1) PA8842901A1 (pt)
TW (1) TW201023858A (pt)
UY (1) UY32128A (pt)
WO (1) WO2010031829A1 (pt)
ZA (1) ZA201102047B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
AU2009293493B2 (en) 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
KR20120106942A (ko) 2009-10-30 2012-09-27 베링거 인겔하임 인터내셔날 게엠베하 Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
MX2012011963A (es) * 2010-04-13 2012-12-17 Janssen Pharmaceuticals Inc Combinacion de un inhibidor macrociclico del virus de la hepatitis c, un no-nucleosido y un nucleosido.
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012041771A1 (en) * 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8466159B2 (en) * 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) * 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9243022B2 (en) * 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2018017989A1 (en) * 2016-07-22 2018-01-25 Janssen Pharmaceuticals, Inc. Combination therapy regimen for treatment of selected hcv genotypes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
MX2008010355A (es) * 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
AR059430A1 (es) * 2006-02-09 2008-04-09 Schering Corp Novedosas combinaciones y metodos de inhibidores del vhc
HRP20110193T1 (hr) * 2006-10-10 2011-05-31 Medivir Ab Inhibitor hcv nukleozida

Also Published As

Publication number Publication date
PA8842901A1 (es) 2010-04-21
CA2737835A1 (en) 2010-03-25
KR20110054056A (ko) 2011-05-24
US20110171174A1 (en) 2011-07-14
AR073603A1 (es) 2010-11-17
UY32128A (es) 2010-03-26
ZA201102047B (en) 2012-08-29
AU2009294622A1 (en) 2010-03-25
WO2010031829A1 (en) 2010-03-25
TW201023858A (en) 2010-07-01
EA201170456A1 (ru) 2011-08-30
ECSP11010902A (es) 2011-06-30
EP2341907A1 (en) 2011-07-13
CN102164602A (zh) 2011-08-24
JP2012502956A (ja) 2012-02-02
MX2011002896A (es) 2011-08-15
CO6351740A2 (es) 2011-12-20
AP2011005608A0 (en) 2011-04-30
IL211599A0 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
ZA201102047B (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a nucleoside
CY2019044I1 (el) Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp)
BRPI0807087A2 (pt) Inibidores de hcv macrocíclicos substituídos de pirimidina
BRPI0719258A2 (pt) Inibidor do hcv nucleosídeo
IL192732A0 (en) Ang2 and vefg inhibitor combinations
BRPI1007027A2 (pt) combinação de um derivado de ciclosporina e nucleosídeos para tratar do hcv
DOP2010000091A (es) Inhibidores de quinasa simil polo
DK2373172T3 (da) Hcv-ns5a-hæmmere
DK2097402T3 (da) Makrocykliske inhibitorer af hepatitis c-virus
BRPI0806945A2 (pt) Formas polimórficas de um inibidor macrocíclico de hcv
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
BRPI0906980A2 (pt) Composição de derivados e maleatados
BR112012005438A2 (pt) inibidores de vírus flaviviridae
IL213278A0 (en) Inhibitors of hcv ns5a
BRPI0916694A2 (pt) combinação antineoplásicas de 4-anilino-3-cianoquinolinas e capecitabina
BRPI0915589A2 (pt) combinação herbicida sinérgica de clomazone e petoxamida
EP2036552A4 (en) SENESCENCE INHIBITOR
EP1984323A4 (en) VIRAL POLYMERASE INHIBITORS
BRPI0910346A2 (pt) compostos de benzopirano e benzoxapina inibidores de pi3k e métodos de uso
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
BRPI0909189A2 (pt) combinações sinergísticas de 5'-metiltioadenosina
DK2332429T3 (da) Handske og vedhæftning dertil
BRPI0920681A2 (pt) inibidores de decahidro-1h-indenoquinolinona e decahidro-3h-ciclopentafenantridinona de cyp17
EP2222662A4 (en) INHIBITORS OF KYNURENINE AMINO TRANSFERASE
BRPI0820834A2 (pt) Inibidor de vórtice

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A SOLICITACAO DO EXAME PRIORITARIO DO PEDIDO DE PATENTE PI 0919404-5, REQUERIDO ATRAVES DO MINISTERIO DA SAUDE POR MEIO DO OFICIO NO 882/2016/SCTIE/MS, COM FULCRO NO PARAGRAFO 1O DO ART. 1O DA RESOLUCAO INPI NO 080, DE 19/03/2013, UMA VEZ QUE O PEDIDO ENCONTRA-SE ARQUIVADO DEFINITIVAMENTE, SENDO DESNECESSARIO REQUERIMENTO DE EXAME PRIORITARIO PARA O MESMO.